Ligand Pharmaceuticals Inc
F:LGDN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Ligand Pharmaceuticals Inc (LGDN) under the Base Case is 170.76 EUR per share.
Compared with the current market price of 276 EUR, the stock appears
Overvalued by 38% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Ligand Pharmaceuticals Does
Ligand Pharmaceuticals is a biotech company that makes money mainly by licensing drug-development technologies to other drugmakers. It does not sell drugs directly to patients. Instead, it helps pharmaceutical and biotech partners create and improve medicines through tools such as formulation know-how and protein-based discovery platforms, then earns fees, milestones, and royalties tied to those partnered products.
- Headquarters
- United States of America US
- Employees
- 47
- IPO date
- Nov 18, 1992
Revenue & Expenses Breakdown
Ligand Pharmaceuticals Inc
Earnings Waterfall
Ligand Pharmaceuticals Inc
Continue LGDN Research
Decided on Ligand Pharmaceuticals? Get an email when LGDN reaches the price you’d buy at. Free with an account.
Other Ligand Pharmaceuticals listings
What is the Intrinsic Value of one LGDN stock?
The intrinsic value for Ligand Pharmaceuticals Inc (LGDN) under the Base Case is 170.76 EUR.
Is LGDN stock undervalued or overvalued?
Compared with the current market price of 276 EUR, the stock appears Overvalued by 38% .
